James S. Mahan III, Chief Executive Officer and Director of Live Oak Bancshares, Inc. (NYSE:LOB), filed a Form 4 on August 21, 2026, disclosing the sale of 20,000 shares of Voting Common Stock across three transactions on August 19 and 20, 2026, all executed …
Director M. Michele Burns filed a Form 4 with the SEC on August 21, 2026, reporting the sale of 3,332 shares of Circle Internet Group, Inc. Class A Common Stock on August 20, 2026, under a pre-established Rule 10b5-1 trading plan.
Daniel Leib, Chief Executive Officer and Director of Donnelley Financial Solutions, Inc., filed a Form 4 on August 21, 2026, disclosing the sale of 9,787 shares of common stock on August 19, 2026.
Joshua T. Mook, Chief Technology Officer of Hyliion Holdings Corp. (NYSE:HYLN), filed a Form 4 on August 21, 2026, disclosing the disposition of 10,700 shares of common stock at $3.33 per share on the same date.
Jose Miguel Oxholm, Chief Legal and Compliance Officer of Hyliion Holdings Corp., filed a Form 4 on August 21, 2026, reporting the disposition of 11,980 shares of common stock at $3.33 per share under an issuer-directed tax withholding arrangement.
Govindaraj Ramasamy, Chief Commercial Officer of Hyliion Holdings Corp. (NYSE:HYLN), filed a Form 4 on August 21, 2026, disclosing a disposition of common stock on that same date.
Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 21, 2026, reporting the sale of 20,000 ordinary shares across three transactions between August 19 and August 21, 2026.
Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Inc., filed a statement of changes in beneficial ownership on August 21, 2026, disclosing a sale of common stock on August 19, 2026, in connection with the vesting of Restricted Stock Units.
Manuela Valente, Chief People Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 21, 2026, disclosing the exercise of share options and the subsequent sale of ordinary shares on August 19, 2026.
A Form 4 filed on August 21, 2026, with the SEC discloses that Ondrej Vlcek, a director of Gen Digital Inc. (NASDAQ:GEN), sold 100,000 shares of common stock on August 19, 2026.